Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

HEALTHCARE REPORTS

wpe11.jpg (7184 bytes)

“Our company is in the medical device space marketing an injectable aesthetic product, ArteFill, that is a treatment for facial wrinkles. As we all know, baby boomers are aging and looking for a way to age gracefully. We have developed the first and only injectable wrinkle filler that has a permanent component that provides a long-term effect compared to the existing dermal fillers on the market that are all temporary in nature and required...” - Click here to visit interview with Diane S. Goostree, President and CEO, Artes Medical, Inc. (ARTE-NASDAQ).

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE |  COVER ARCHIVES  |  INDEX  |  CONTACT  |  FINANCIALS |  MARKETING SERVICES | HOME PAGE


CEOCFO-Members Login
Become A Member!
More headlines.....

Focused On Developing A Vaccine To Treat Diseases Caused By HIV-1, GeoVax Is Preparing To Enter Phase 2 Clinical Trials With Their DNA Vaccine, Which Also Has An MVA Component As A Booster
 (GOVX-OTC: BB)

With Two Programs In Phase 3 Studies For PAD Patients, Another In Phase 3 For Melanoma, And Multiple Programs Advancing For Infectious Diseases, Vical’s DNA Vaccine Technology Has Arrived (VICL-NASDAQ)

Universal Health Services’ Growth Strategy Involves Building Hospitals In Communities Where There Is An Increasing Population And Therefore, A Great Need For Their Services (UHS-NYSE)

IntelGenx Technologies Is Focused On Providing Development Services To The Pharmaceutical Industry Using Their Proprietary Orally Administered Drug Delivery Technology (IGXT-OTC: BB)

Alseres Pharmaceuticals Is In Phase III Clinical Trials With Their Altropane Technology That Will Allow Them To Diagnose Parkinson’s Disease And In Phase II With Their Cethrin Recombinant-Protein-Based Drug For Nerve Repair In Spinal Cord Injury - (ALSE-NASDAQ)

Cyplasin Biomedical Has Discovered That Their Protein That Originally Came From The Sea Hare Has Great Selectivity And Is Able To Target Cancer Cells And Not Harm Normal Cells - Cyplasin Biomedical Ltd. (CYPL-OTC: BB)

All rights reserved - ceocfointerviews.com
Left click on company name below to access full-text interview!

Healthcare - Medical Appliances & Equipment

Accuray Offers A Non-Invasive, Painless, Bloodless, Scar-less Alternative To Many Patients Whose Tumors Would Otherwise Be Inoperable With Their CyberKnife®, Which Is A Medical Robot That Delivers Radiation To Kill Tumors With Sub-Millimeter Accuracy


Robert E. McNamara
Senior Vice President, CFO
 Accuray Incorporated (ARAY-NASDAQ)
**********

 

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.